What to Do as a Gynecologic Oncologist during the COVID-19 Pandemic ? : MEMAGO Statement

Q4 Medicine
D. Atallah, Y. Khalek, M. Meydanli, N. Kassis, R. Abdallah, A. Ayhan, C. Khoury, G. Chahine, Ç. Taşkıran, F. Köse, M. Seoud
{"title":"What to Do as a Gynecologic Oncologist during the COVID-19 Pandemic ? : MEMAGO Statement","authors":"D. Atallah, Y. Khalek, M. Meydanli, N. Kassis, R. Abdallah, A. Ayhan, C. Khoury, G. Chahine, Ç. Taşkıran, F. Köse, M. Seoud","doi":"10.12816/0057441","DOIUrl":null,"url":null,"abstract":"The SARS-Cov-2 virus pandemic causes an acute public health emergency with millions of infected patients and thousands of deaths The infection makes adults prone to severe and fatal consequences, especially when they suffer several comorbidities Our oncologic patients are the most susceptible to its severe repercussions because of their initial diagnosis and the immunosuppressive adjuvant and neoadjuvant treatments they receive The Chinese CDC reported a 5 6% risk of mortality among cancer patients compared to 0 9% in the general population;likewise, other studies showed a twofold higher risk of death in this patients’ subgroup In order to maintain the best quality of medical services during this crisis, along with the safety of healthcare providers, accurate triage of our oncologic patients must be done before any medical or surgical intervention to decide whether or not postponing treatments may be considered, without risking the disease progression and patients’ worsening outcomes, otherwise inpatient and outpatient special precautions must be followed whenever interventions are currently scheduled, according to each gynecologic cancer type The disease is worldwide but local and regional circumstances vary, thus practice guidelines must be individualized according to each country virus prevalence and available medical resources, in order to limit the burden of the COVID-19 infection on the health system during the crisis and the upcoming months after its resolution","PeriodicalId":39521,"journal":{"name":"Journal Medical Libanais","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal Medical Libanais","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12816/0057441","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The SARS-Cov-2 virus pandemic causes an acute public health emergency with millions of infected patients and thousands of deaths The infection makes adults prone to severe and fatal consequences, especially when they suffer several comorbidities Our oncologic patients are the most susceptible to its severe repercussions because of their initial diagnosis and the immunosuppressive adjuvant and neoadjuvant treatments they receive The Chinese CDC reported a 5 6% risk of mortality among cancer patients compared to 0 9% in the general population;likewise, other studies showed a twofold higher risk of death in this patients’ subgroup In order to maintain the best quality of medical services during this crisis, along with the safety of healthcare providers, accurate triage of our oncologic patients must be done before any medical or surgical intervention to decide whether or not postponing treatments may be considered, without risking the disease progression and patients’ worsening outcomes, otherwise inpatient and outpatient special precautions must be followed whenever interventions are currently scheduled, according to each gynecologic cancer type The disease is worldwide but local and regional circumstances vary, thus practice guidelines must be individualized according to each country virus prevalence and available medical resources, in order to limit the burden of the COVID-19 infection on the health system during the crisis and the upcoming months after its resolution
在新冠肺炎大流行期间,作为一名妇科肿瘤医生该做什么?:MEMAGO声明
严重急性呼吸系统综合征冠状病毒2型大流行导致了一场急性公共卫生紧急事件,数百万感染患者和数千人死亡。感染使成年人容易遭受严重和致命的后果,尤其是当他们患有多种合并症时。我们的肿瘤患者最容易受到其严重影响,因为他们的初步诊断以及他们接受的免疫抑制辅助和新辅助治疗。中国疾病控制与预防中心报告,癌症患者的死亡率为5.6%,而普通人群的死亡率为09%;同样,其他研究表明,该患者亚组的死亡风险高出两倍。为了在这场危机期间保持最佳的医疗服务质量,以及医疗保健提供者的安全,在进行任何医疗或外科干预之前,必须对我们的肿瘤患者进行准确的分诊,以决定是否可以考虑推迟治疗,在不冒疾病进展和患者恶化的风险的情况下,否则,根据每种妇科癌症类型,无论何时安排干预措施,都必须遵循住院和门诊特殊预防措施,因此,实践指南必须根据每个国家的病毒流行率和可用的医疗资源进行个性化,以便在危机期间和危机解决后的几个月内限制新冠肺炎感染对卫生系统的负担
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal Medical Libanais
Journal Medical Libanais Medicine-Medicine (all)
CiteScore
0.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信